Press Releases

Press Releases

Applied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Apr 06, 2021
SOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,875,000 shares of its common stock, which

Applied Molecular Transport Announces Pricing of Public Offering of Common Stock

Mar 31, 2021
SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of

Applied Molecular Transport Announces Proposed Public Offering of Common Stock

Mar 29, 2021
SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock.

Applied Molecular Transport Appoints Earl Douglas as General Counsel

Mar 22, 2021
Company continues to strengthen key functions of corporate leadership Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program beginning in the second half of 2021 Company expanded clinical pipeline with second program,

Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 19, 2021
Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program, in multiple ulcerative colitis populations and rheumatoid arthritis,

Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference

Mar 09, 2021
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

Mar 01, 2021
Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects IL-22 deficiency implicated in broad range of gastrointestinal-focused and peripheral diseases ranging from ulcerative colitis to

Applied Molecular Transport to Present at SVB Leerink 10th Annual Global Healthcare Conference

Feb 17, 2021
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB

Applied Molecular Transport Appoints Douglas Rich as Chief Technical Officer

Jan 19, 2021
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership